![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: IFNG |
Gene summary for IFNG |
![]() |
Gene information | Species | Human | Gene symbol | IFNG | Gene ID | 3458 |
Gene name | interferon gamma | |
Gene Alias | IFG | |
Cytomap | 12q15 | |
Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | P01579 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3458 | IFNG | LZE4T | Human | Esophagus | ESCC | 1.47e-07 | 7.07e-01 | 0.0811 |
3458 | IFNG | LZE6T | Human | Esophagus | ESCC | 1.87e-12 | 1.66e+00 | 0.0845 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00326808 | Prostate | Tumor | regulation of tumor necrosis factor production | 44/3246 | 181/18723 | 1.05e-02 | 4.38e-02 | 44 |
GO:00717068 | Prostate | Tumor | tumor necrosis factor superfamily cytokine production | 45/3246 | 186/18723 | 1.06e-02 | 4.42e-02 | 45 |
GO:19035558 | Prostate | Tumor | regulation of tumor necrosis factor superfamily cytokine production | 45/3246 | 186/18723 | 1.06e-02 | 4.42e-02 | 45 |
GO:00603334 | Prostate | Tumor | interferon-gamma-mediated signaling pathway | 10/3246 | 27/18723 | 1.17e-02 | 4.79e-02 | 10 |
GO:003425025 | Skin | AK | positive regulation of cellular amide metabolic process | 43/1910 | 162/18723 | 2.77e-09 | 2.40e-07 | 43 |
GO:000961519 | Skin | AK | response to virus | 63/1910 | 367/18723 | 2.53e-05 | 4.54e-04 | 63 |
GO:00420637 | Skin | AK | gliogenesis | 53/1910 | 301/18723 | 5.42e-05 | 8.29e-04 | 53 |
GO:00100017 | Skin | AK | glial cell differentiation | 40/1910 | 225/18723 | 3.45e-04 | 3.47e-03 | 40 |
GO:00217822 | Skin | AK | glial cell development | 24/1910 | 116/18723 | 5.74e-04 | 5.11e-03 | 24 |
GO:00487084 | Skin | AK | astrocyte differentiation | 18/1910 | 81/18723 | 1.14e-03 | 8.81e-03 | 18 |
GO:000181917 | Skin | AK | positive regulation of cytokine production | 67/1910 | 467/18723 | 2.59e-03 | 1.67e-02 | 67 |
GO:00429824 | Skin | AK | amyloid precursor protein metabolic process | 19/1910 | 95/18723 | 3.08e-03 | 1.92e-02 | 19 |
GO:00972425 | Skin | AK | amyloid-beta clearance | 10/1910 | 38/18723 | 3.89e-03 | 2.29e-02 | 10 |
GO:00343419 | Skin | AK | response to interferon-gamma | 25/1910 | 141/18723 | 4.25e-03 | 2.48e-02 | 25 |
GO:00429874 | Skin | AK | amyloid precursor protein catabolic process | 14/1910 | 68/18723 | 7.90e-03 | 4.00e-02 | 14 |
GO:00713467 | Skin | AK | cellular response to interferon-gamma | 21/1910 | 118/18723 | 7.97e-03 | 4.03e-02 | 21 |
GO:00140022 | Skin | AK | astrocyte development | 10/1910 | 43/18723 | 9.86e-03 | 4.77e-02 | 10 |
GO:0009615110 | Skin | SCCIS | response to virus | 32/919 | 367/18723 | 1.23e-03 | 1.45e-02 | 32 |
GO:20002732 | Skin | SCCIS | positive regulation of signaling receptor activity | 8/919 | 45/18723 | 1.40e-03 | 1.59e-02 | 8 |
GO:00421164 | Skin | SCCIS | macrophage activation | 13/919 | 106/18723 | 2.05e-03 | 2.11e-02 | 13 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa0305028 | Esophagus | ESCC | Proteasome | 44/4205 | 46/8465 | 1.05e-11 | 1.60e-10 | 8.21e-11 | 44 |
hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa051609 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
hsa0406629 | Esophagus | ESCC | HIF-1 signaling pathway | 75/4205 | 109/8465 | 3.66e-05 | 1.68e-04 | 8.60e-05 | 75 |
hsa0465727 | Esophagus | ESCC | IL-17 signaling pathway | 66/4205 | 94/8465 | 3.93e-05 | 1.75e-04 | 8.99e-05 | 66 |
hsa0514525 | Esophagus | ESCC | Toxoplasmosis | 76/4205 | 112/8465 | 6.83e-05 | 2.90e-04 | 1.48e-04 | 76 |
hsa051527 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
hsa043507 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa052356 | Esophagus | ESCC | PD-L1 expression and PD-1 checkpoint pathway in cancer | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
hsa051425 | Esophagus | ESCC | Chagas disease | 65/4205 | 102/8465 | 2.81e-03 | 7.59e-03 | 3.89e-03 | 65 |
hsa046599 | Esophagus | ESCC | Th17 cell differentiation | 68/4205 | 108/8465 | 3.53e-03 | 9.30e-03 | 4.76e-03 | 68 |
hsa0461230 | Esophagus | ESCC | Antigen processing and presentation | 51/4205 | 78/8465 | 3.57e-03 | 9.34e-03 | 4.78e-03 | 51 |
hsa0532320 | Esophagus | ESCC | Rheumatoid arthritis | 59/4205 | 93/8465 | 4.98e-03 | 1.27e-02 | 6.52e-03 | 59 |
hsa046585 | Esophagus | ESCC | Th1 and Th2 cell differentiation | 58/4205 | 92/8465 | 6.49e-03 | 1.60e-02 | 8.19e-03 | 58 |
hsa046607 | Esophagus | ESCC | T cell receptor signaling pathway | 63/4205 | 104/8465 | 1.60e-02 | 3.60e-02 | 1.84e-02 | 63 |
hsa05418310 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa0305037 | Esophagus | ESCC | Proteasome | 44/4205 | 46/8465 | 1.05e-11 | 1.60e-10 | 8.21e-11 | 44 |
hsa0516435 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa0516016 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | Breast | DCIS |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | Breast | Healthy |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | Breast | IDC |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | Cervix | ADJ |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | Cervix | CC |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | Cervix | Healthy |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | Cervix | Precancer |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | Endometrium | ADJ |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | Endometrium | AEH |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | Endometrium | EEC |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | Endometrium | Healthy |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | GC | ADJ |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | GC | GC |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | HNSCC | ADJ |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | HNSCC | Healthy |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | HNSCC | OSCC |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | HNSCC | Precancer |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | Liver | Healthy |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | Liver | Precancer |
IFNG | IFNGR1_IFNGR2 | IFNG_IFNGR1_IFNGR2 | IFN-II | Lung | AAH |
Page: 1 2 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IFNG | SNV | Missense_Mutation | c.324C>G | p.Asn108Lys | p.N108K | P01579 | protein_coding | deleterious(0.02) | benign(0.342) | TCGA-A7-A26F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
IFNG | SNV | Missense_Mutation | rs755519988 | c.388N>T | p.Arg130Cys | p.R130C | P01579 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
IFNG | SNV | Missense_Mutation | c.31N>G | p.Gln11Glu | p.Q11E | P01579 | protein_coding | deleterious(0.02) | possibly_damaging(0.732) | TCGA-C5-A2LS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
IFNG | SNV | Missense_Mutation | c.365C>T | p.Ser122Leu | p.S122L | P01579 | protein_coding | deleterious(0.01) | possibly_damaging(0.617) | TCGA-A6-6654-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
IFNG | SNV | Missense_Mutation | c.105N>T | p.Lys35Asn | p.K35N | P01579 | protein_coding | deleterious(0.04) | possibly_damaging(0.843) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
IFNG | SNV | Missense_Mutation | c.256N>T | p.Asp86Tyr | p.D86Y | P01579 | protein_coding | deleterious(0) | benign(0.187) | TCGA-D5-5539-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fu | PD | |
IFNG | SNV | Missense_Mutation | rs201359065 | c.479G>A | p.Arg160Gln | p.R160Q | P01579 | protein_coding | tolerated(0.23) | benign(0.015) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
IFNG | SNV | Missense_Mutation | novel | c.121G>T | p.Gly41Cys | p.G41C | P01579 | protein_coding | deleterious(0) | benign(0.238) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
IFNG | SNV | Missense_Mutation | c.263G>A | p.Ser88Asn | p.S88N | P01579 | protein_coding | tolerated(0.5) | benign(0) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
IFNG | SNV | Missense_Mutation | novel | c.291N>T | p.Lys97Asn | p.K97N | P01579 | protein_coding | tolerated(0.06) | probably_damaging(0.91) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3458 | IFNG | DRUGGABLE GENOME | CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | 10823419 | |
3458 | IFNG | DRUGGABLE GENOME | CIGB-128 | |||
3458 | IFNG | DRUGGABLE GENOME | Emapalumab | EMAPALUMAB | ||
3458 | IFNG | DRUGGABLE GENOME | METHYLPREDNISOLONE | METHYLPREDNISOLONE | 9396353 | |
3458 | IFNG | DRUGGABLE GENOME | PEFLOXACIN | PEFLOXACIN | 8673851 | |
3458 | IFNG | DRUGGABLE GENOME | SURAMIN | SURAMIN | 1899122 | |
3458 | IFNG | DRUGGABLE GENOME | MONOCLONAL ANTIBODY 17-1A | 2121912 | ||
3458 | IFNG | DRUGGABLE GENOME | BLEOMYCIN | BLEOMYCIN | 8556994 | |
3458 | IFNG | DRUGGABLE GENOME | CISPLATIN | CISPLATIN | 8044830 | |
3458 | IFNG | DRUGGABLE GENOME | MELATONIN | MELATONIN | 7722866 |
Page: 1 2 3 4 |